MapLight Therapeutics (MPLT) Assets Average (2025)
MapLight Therapeutics (MPLT) reported Assets Average of $368.4 million for Q4 2025, up 86.92% sequentially from $197.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Assets Average (2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 1 years of Assets Average data on file, last reported at $368.4 million in Q4 2025.
- For the quarter ending Q4 2025, Assets Average changed N/A year-over-year to $368.4 million; the trailing twelve-month figure through Dec 2025 stood at $368.4 million (changed N/A YoY), and the FY2025 full-year result was $308.2 million, changed N/A from the prior year.
- Assets Average climbed to $368.4 million in Q4 2025, from $197.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $368.4 million in Q4 2025 to a low of $197.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.30 Bn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | 368.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 368.37 Mn |
| Sep 30, 2025 | 197.07 Mn |